October 11, 2024
There is a temporary manufacturing shortage of the drug UDENYCA® (pegfilgrastim-cbqv). As a result, we have approved the use of NYVEPRIA™ as an alternative medication when a prior authorization for UDENYCA is already on file for a patient with Cigna HealthcareSM coverage. The manufacturer expects the supply interruption to be solved by early November. NYVEPRIA is approved as an alternative through December 31, 2024.
What this means
Additional information
The following chart details the current status and Healthcare Common Procedure Coding System (HCPCS) codes for UDENYCA and alternative medications.
| Drug brand name | Generic drug name | HCPCS code | Current status |
| UDENYCA® | pegfilgrastim-cbqv | Q5111 | Supply interruption at the manufacturer |
| UDENYCA® Autoinjector | pegfilgrastim-cbqv | Q5111 | Supply interruption at the manufacturer |
| UDENYCA® ON-BODY Injector | pegfilgrastim-cbqv | Q5111 | Supply interruption at the manufacturer |
| NYVEPRIA™ | pegfilgrastim-apgf | Q5122 | Approved UDENYCA® alternative |
| Fulphila® | pegfilgrastim-jmdb | Q5108 | Standard prior authorization required |
| Fylnetra® | pegfilgrastim-pbbk | Q5130 | Standard prior authorization required |
| Neulasta® Onpro® | pegfilgrastim | J2506 | Standard prior authorization required |
| Neulasta® Injection | pegfilgrastim | J2506 | Standard prior authorization required |
| STIMUFEND® | pegfilgrastim-fpgk | Q5127 | Standard prior authorization required |
| Ziextenzo® | pegfilgrastim-bmez | Q5120 | Standard prior authorization required |
Please let us know what you think of the Provider Newsroom information and news.
Contact Us
